for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Anavex Life Sciences Corp

AVXL.OQ

Latest Trade

11.73USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

2.21

 - 

28.67

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Anavex Life Sciences Posts Q1 Loss Per Share $0.12

Feb 11 (Reuters) - Anavex Life Sciences Corp <AVXL.O>::ANAVEX LIFE SCIENCES REPORTS FISCAL 2021 FIRST QUARTER FINANCIAL RESULTS AND BUSINESS OUTLOOK.Q1 LOSS PER SHARE $0.12.

Anavex Life Sciences Reports Fiscal 2020 Year End Financial Results And Clinical Program Updates

Dec 28 (Reuters) - Anavex Life Sciences Corp <AVXL.O>::ANAVEX LIFE SCIENCES REPORTS FISCAL 2020 YEAR END FINANCIAL RESULTS AND CLINICAL PROGRAM UPDATES.ANAVEX LIFE SCIENCES CORP - PLAN TO ADVANCE AVATAR ADULT RETT SYNDROME STUDY INTO A PIVOTAL PHASE 2/3 CLINICAL TRIAL.

Anavex Life Sciences Announces Anavex 2-73 (Blarcamesine) Meets Primary And Secondary Endpoints

Dec 15 (Reuters) - Anavex Life Sciences Corp <AVXL.O>::ANAVEX LIFE SCIENCES ANNOUNCES ANAVEX 2-73 (BLARCAMESINE) MEETS PRIMARY AND SECONDARY ENDPOINTS IN PLACEBO-CONTROLLED U.S. PHASE 2 CLINICAL TRIAL FOR TREATMENT OF ADULT PATIENTS WITH RETT SYNDROME.ANAVEX LIFE SCIENCES CORP - EFFICACY ENDPOINTS DEMONSTRATED STATISTICALLY SIGNIFICANT AND CLINICALLY MEANINGFUL REDUCTIONS IN RETT SYNDROME SYMPTOMS.ANAVEX LIFE SCIENCES CORP - KEY MILESTONE MET TO ADVANCE REGULATORY APPROVAL PATHWAY FOR ADULT PATIENTS WITH RETT SYNDROME.

Anavex Life Sciences Announces Positive Results On Phase 2 Clinical Trial In Parkinson’S Disease Dementia

Oct 15 (Reuters) - Anavex Life Sciences Corp <AVXL.O>::ANAVEX LIFE SCIENCES ANNOUNCES POSITIVE RESULTS FROM PROOF OF CONCEPT CONTROLLED PHASE 2 CLINICAL TRIAL EVALUATING ANAVEX®2-73 (BLARCAMESINE) IN PARKINSON’S DISEASE DEMENTIA.ANAVEX LIFE SCIENCES CORP - STUDY FOUND THAT ANAVEX2-73 (BLARCAMESINE) WAS SAFE AND WELL TOLERATED IN ORAL DOSES UP TO 50 MG ONCE DAILY.ANAVEX LIFE SCIENCES - RESULTS SHOW STATISTICALLY SIGNIFICANT IMPROVEMENTS IN COGNITIVE DRUG RESEARCH (CDR) COMPUTERIZED ASSESSMENT SYSTEM ANALYSIS.ANAVEX - AFTER COMPLETING TRIAL, PARTICIPANTS WERE ABLE TO ENROLL IN VOLUNTARY 48-WEEK OPEN-LABEL EXTENSION STUDY, ANAVEX 2-73-PDD-EP-001.

Anavex Life Sciences Q3 Loss Per Share $0.11

Aug 6 (Reuters) - Anavex Life Sciences Corp <AVXL.O>::ANAVEX LIFE SCIENCES REPORTS FISCAL 2020 THIRD QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES.Q3 LOSS PER SHARE $0.11.Q3 EARNINGS PER SHARE ESTIMATE $-0.14 -- REFINITIV IBES DATA.CASH AND CASH EQUIVALENTS OF $27.6 MILLION AT JUNE 30.

Anavex Life Sciences Q2 Loss Per Share $0.12

May 7 (Reuters) - Anavex Life Sciences Corp <AVXL.O>::ANAVEX LIFE SCIENCES REPORTS FISCAL 2020 SECOND QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES.Q2 LOSS PER SHARE $0.12.Q2 EARNINGS PER SHARE ESTIMATE $-0.16 -- REFINITIV IBES DATA.

Anavex Life Sciences Corp Files Prospectus Supplement Related To Issuance, Sale Of Up To $30.3 Million In Common Shares To Lincoln Park Capital Fund, Llc

May 1 (Reuters) - Anavex Life Sciences Corp <AVXL.O>::ANAVEX LIFE SCIENCES CORP FILES PROSPECTUS SUPPLEMENT RELATES TO ISSUANCE, SALE OF UP TO $30.3 MILLION IN COMMON SHARES TO LINCOLN PARK CAPITAL FUND, LLC.

Anavex Life Sciences Corp - May Offer And Sell Shares Of Common Stock Having Offering Price Of Up To $50 Million From Time To Time

May 1 (Reuters) - Anavex Life Sciences Corp <AVXL.O>::ANAVEX LIFE SCIENCES CORP - MAY OFFER AND SELL SHARES OF COMMON STOCK HAVING OFFERING PRICE OF UP TO $50 MILLION FROM TIME TO TIME - SEC FILING.

Anavex Life Sciences Q1 Loss Per Share $0.12

Anavex Life Sciences Corp <AVXL.O>::ANAVEX LIFE SCIENCES REPORTS FISCAL 2020 FIRST QUARTER FINANCIAL RESULTS AND PROVIDES CLINICAL STUDY UPDATES.Q1 LOSS PER SHARE $0.12.

Anavex Life Sciences -Fast Track Designation Granted By FDA For Rett Syndrome Treatment

Feb 3 (Reuters) - Anavex Life Sciences Corp <AVXL.O>::ANAVEX LIFE SCIENCES ANNOUNCES FAST TRACK DESIGNATION GRANTED BY U.S. FDA FOR ANAVEX®2-73 (BLARCAMESINE) CLINICAL DEVELOPMENT PROGRAM FOR THE TREATMENT OF RETT SYNDROME.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up